🔗 Share this article Social Media Influencers Driving Unofficial Trade for Unapproved Weight-Loss Drug An underground market for unapproved slimming drugs is being driven by social media fitness personalities and vendors on communication apps, based on recent findings. Investigational Drug Gaining Traction Online Retatrutide, which remains in research studies, is being promoted by social media influencers for its supposed weight-reducing properties. Viewers are urged to contact these accounts directly for supplier links, while also obtaining discount codes. Thriving Trade on Messaging Platforms Additionally, a flourishing market exists on Telegram, where groups with numerous of members share “before and after” photos, injection guides and assertions of rapid British shipping. Sellers market the substance there before redirecting customers to other platforms for transactions. Learning About The Experimental Drug This medication is an investigational injection developed by US drugmaker Eli Lilly. The treatment targets three intestinal hormones – GLP-1, glucose-dependent insulinotropic polypeptide and pancreatic hormone. Preliminary studies indicate it could help patients reduce up to 25% of their body weight. Referred to as the “triple G”, the substance is being promoted digitally as the next Ozempic. Medical Professionals Express Concerns Nevertheless, physicians and pharmacists have warned that the sale of what remains an unapproved medication in the UK is a cause for concern and could result in users injecting substances of uncertain source. Several experts said the popularity for the experimental drug could be linked to the rising cost of approved slimming products such as Mounjaro. Regulatory Position and Implementation Marketing retatrutide on social media or messaging apps is prohibited in the United Kingdom, as it is an unapproved drug that must not be marketed or supplied for human use under the British medical regulations. Several influencers attempt to sidestep the regulations by referring to the substance as a “research chemical” or describing it as “not for human consumption”. The substance is not a controlled substance, but advertising and supply can still breach pharmaceutical, marketing, and consumer laws, risking fines, legal action or prison. Service Response and Content Removal According to TikTok, the platform has taken down violative content and prohibited associated hashtags and query recommendations. The company stated it was dedicated to keeping the platform secure and investing in enhancing compliance measures. Online Trading Operations Investigations also found communities with up to nine thousand members marketing retatrutide using Telegram's built-in discovery tool, which functions like a online catalog. Entering “retatrutide” instantly displays groups with thousands of users, filled with images of slimming results, positive reviews and step-by-step instructions for mixing or injecting at home. Within minutes of joining one community, a seller shared WhatsApp details, where the majority of transactions occur. The seller sent an guidebook and promised shipping within 48 hours. When asked whether the product was genuine, one vendor said: “You can’t be sure.” Another shared a image of a supposed laboratory certificate. None inquired about body mass, health issues or past usage. Product Information and Pricing Within these communities, posts display black plastic parcels with postal service stickers, stating to contain new batches. One message stated: “It took eight of us to load them this morning.” Buyers can choose between dry substance containers, mixed at home with purified liquid, or pre-filled pens usually sold at £160 for 20mg. When questioned how long a injector should be used, vendors give conflicting answers ranging from a several days to “depends on your body”. Service Oversight and Security Measures A spokesperson for the messaging service said it regularly monitored harmful material on its service including content that promoted the “misuse of controlled medications”. The organization noted that it eliminated “millions of pieces of harmful content each day”. Healthcare Expert Warnings “People are injecting substances they can’t verify. Even if the research behind this drug is sound, these online products may not include what they advertise,” said Jason Murphy, the director of pharmaceutical services at Chemist4U. Dr Crystal Wyllie of Asda Online Doctor linked the increase in interest to recent price rises for approved weight-loss drugs such as Mounjaro. “With prices increasing, individuals are using online platforms. But fake treatments are extremely risky. You can’t be certain what’s inside or whether the conditions they were produced in was clean,” she explained. Her team has already seen patients harmed by self-injection from unverified sources. “We understand the disappointment, but buying from messaging apps or WhatsApp is taking chances with your well-being,” said Wyllie. “These substances could be contaminated or improperly measured.” Producer Statement A spokesperson from Eli Lilly stated retatrutide was in third stage clinical trials and had not been evaluated or approved by any regulatory agency anywhere in the world. “Consequently at this point no one can sell [it] for human use,” they explained, adding that any product “misleadingly claiming itself as a Lilly investigational substance not yet authorized … may expose patients to possibly serious health risks”.